NCT05210517

SGLT2 Inhibition: Uric Acid Excretion Study

Uric Acid Excretion Study: Open-label Randomised Cross Over Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Amsterdam UMC, location VUmc · Academic / Other
• Sex: All
• Age: 35 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.

Detailed description

SGTL2 inhibitors improve cardiovascular and kidney outcomes. The underlying mechanisms are incompletely understood. SGLT2 inhibitors are known to reduce plasma uric acid likely by enhanced urinary uric acid excretion. In this study the investigators will study the effects of SGLT2 inhibit on uric acid levels and excretion in detail, linking it to the role of glucosuria and Uric acid transporter (URAT1) which in rodents was indispensable for the glucose-lowering effects of SGLT2 inhibition.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Empagliflozin 25 MG	25 once daily one week treatment
DRUG	Benzbromaron	100 mg once daily 1 one week treatment
DRUG	Empagliflozin 25 MG + benzbromarone 100 mg	combined treatment once daily for one week

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-06-08
• Completion: 2021-09-01
• First posted: 2022-01-27
• Last updated: 2023-05-01

Locations

1 site across 1 country: Netherlands